SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00114-9. doi: 10.1016/j.clml.2024.03.007. Online ahead of print.ABSTRACTChimeric antigen receptor T-cell (CAR-T) therapy has significantly impacted treatment algorithms and clinical outcomes for a variety of patients with hematologic malignancies over the past decade. The field of cellular immunotherapy is currently experiencing a rapid expansion of the number of patients eligible for CAR-T therapies as approvals are being seen in earlier lines of therapy. With the expanded patients eligible for these therapies, more treatment centers will be necessary to keep up with d...
Source: Clinical Lymphoma and Myeloma - April 20, 2024 Category: Cancer & Oncology Authors: Timothy J Voorhees Evandro Bezerra Nathan Denlinger Samantha Jaglowski Marcos de Lima Source Type: research
BCMA Directed Bispecific Antibody Induced Tumor Flare in Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2024 Mar 16:S2152-2650(24)00109-5. doi: 10.1016/j.clml.2024.03.002. Online ahead of print.NO ABSTRACTPMID:38643030 | DOI:10.1016/j.clml.2024.03.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 20, 2024 Category: Cancer & Oncology Authors: Chandramouli Nagarajan Martin Wong Eu Jo Thomas G Martin Source Type: research
Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions
Clin Lymphoma Myeloma Leuk. 2024 Mar 27:S2152-2650(24)00135-6. doi: 10.1016/j.clml.2024.03.010. Online ahead of print.ABSTRACTMantle cell lymphoma (MCL) is a rare, incurable non-Hodgkin's lymphoma characterized by naive B cells infiltrating the lymphoid follicle's mantle zone. A key feature of MCL is the cytogenetic abnormality t(11;14) (q13:q14), found in 95% of cases, leading to Cyclin D1 overexpression resulting in uncontrolled cell cycle progression and genetic instability. Occasionally, Cyclin D2 or D3 overexpression can substitute for Cyclin D1, causing similar effects. The transcription factor SOX11 is a hallmark of...
Source: Clinical Lymphoma and Myeloma - April 19, 2024 Category: Cancer & Oncology Authors: Lara Gallucci Figorelle Peterson Tiago Galv ão Felipe Matheus Ribeiro de Lima Patricia Marimon Nathalia Pentagna Cristiane Milito Rony Schaffel Katia Carneiro Source Type: research
SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2024 Mar 16:S2152-2650(24)00115-0. doi: 10.1016/j.clml.2024.03.008. Online ahead of print.ABSTRACTMonoclonal proteins are common, with a prevalence in the United States around 5% and the incidence increases with age. Although most patients are asymptomatic, the vast majority of cases are caused by a clonal plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions with variable risk of progression to multiple myeloma (MM). In recent years, significant progress has been made to better understand the f...
Source: Clinical Lymphoma and Myeloma - April 19, 2024 Category: Cancer & Oncology Authors: Timothy Schmidt Zhubin Gahvari Natalie S Callander Source Type: research
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
Clin Lymphoma Myeloma Leuk. 2024 Mar 22:S2152-2650(24)00112-5. doi: 10.1016/j.clml.2024.03.005. Online ahead of print.ABSTRACTImmunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therap...
Source: Clinical Lymphoma and Myeloma - April 16, 2024 Category: Cancer & Oncology Authors: Noopur S Raje Adam D Cohen Krina K Patel Niels W C J van de Donk Joshua Richter Jesus San-Miguel Source Type: research
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
Clin Lymphoma Myeloma Leuk. 2024 Mar 22:S2152-2650(24)00112-5. doi: 10.1016/j.clml.2024.03.005. Online ahead of print.ABSTRACTImmunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therap...
Source: Clinical Lymphoma and Myeloma - April 16, 2024 Category: Cancer & Oncology Authors: Noopur S Raje Adam D Cohen Krina K Patel Niels W C J van de Donk Joshua Richter Jesus San-Miguel Source Type: research
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece
CONCLUSION: In this real-world Len-exposed cohort, Len-refractory patients receiving 1L Len experienced poorer survival outcomes than non-Len-refractory patients, highlighting the unmet need in this patient population which has driven the development of novel therapies.PMID:38616479 | DOI:10.1016/j.clml.2024.03.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 15, 2024 Category: Cancer & Oncology Authors: Efstathios Kastritis Ioannis Ntanasis-Stathopoulos Foteini Theodorakakou Magdalini Migkou Maria Roussou Panagiotis Malandrakis Nikolaos Kanellias Evangelos Eleutherakis-Papaiakovou Despina Fotiou Vassiliki Spiliopoulou Maria Gavriatopoulou Sachin Patel Is Source Type: research
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece
CONCLUSION: In this real-world Len-exposed cohort, Len-refractory patients receiving 1L Len experienced poorer survival outcomes than non-Len-refractory patients, highlighting the unmet need in this patient population which has driven the development of novel therapies.PMID:38616479 | DOI:10.1016/j.clml.2024.03.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 15, 2024 Category: Cancer & Oncology Authors: Efstathios Kastritis Ioannis Ntanasis-Stathopoulos Foteini Theodorakakou Magdalini Migkou Maria Roussou Panagiotis Malandrakis Nikolaos Kanellias Evangelos Eleutherakis-Papaiakovou Despina Fotiou Vassiliki Spiliopoulou Maria Gavriatopoulou Sachin Patel Is Source Type: research
Monoclonal gammopathies of renal significance
Clin Med (Lond). 2023 May;23(3):250-253. doi: 10.7861/clinmed.2023-RM3.ABSTRACTThe term monoclonal gammopathies of renal significance (MGRS) encompasses a group of renal histopathological lesions fulfilling two criteria: (a) they are caused by nephrotoxic monoclonal immunoglobulins and (b) the monoclonal immunoglobulins are produced by small B-cell or plasma cell clones which do not meet the criteria for multiple myeloma or malignant lymphoma. Here, we provide a review of the MGRS definition and related terminology and elaborate on the diagnostic approach and treatment principles from the general physician perspective.PMID...
Source: Clinical Lymphoma and Myeloma - April 13, 2024 Category: Cancer & Oncology Authors: Sahana Gnanasampanthan Andreas Kousios Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
CONCLUSIONS: Overall, this study serves as the first to delineate toxicity profiles associated with various available CAR T products. By better understanding associated toxicities, it may become possible to tailor therapies towards individual patients and anticipate the development of toxicities at earlier stages.PMID:38582666 | DOI:10.1016/j.clml.2024.02.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 6, 2024 Category: Cancer & Oncology Authors: Samuel Yamshon Caitlin Gribbin Mohammad Alhomoud Nora Chokr Zhengming Chen Michelle Demetres Michelle Pasciolla John Leonard Tsiporah Shore Peter Martin Source Type: research
Average Temperature as a Marker of Lymphoma-Associated HLH
CONCLUSION: These results demonstrate that a 12-hour mean temperature may add value and diagnostic certainty to the first-line investigations for HLH associated with LPD. The moderately high sensitivity and specificity achieved with this dataset supports the need for further research into whether the test retains validity in larger patient groups.PMID:38582667 | DOI:10.1016/j.clml.2024.02.016 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 6, 2024 Category: Cancer & Oncology Authors: Cameron Clark Jack Goddard Rachel Tattersall Nick Morley Source Type: research
